aTyr Pharma Competitors

Thermo Fisher Scientific (NYSE:TMO) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 0.4% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and aTyr Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Thermo Fisher Scientific and aTyr Pharma, as provided by MarketBeat.com.

Thermo Fisher Scientific presently has a consensus price target of $529.6667, suggesting a potential upside of 17.68%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Thermo Fisher Scientific.

Volatility and Risk

Thermo Fisher Scientific has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Thermo Fisher Scientific and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Thermo Fisher Scientific has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

90.0% of Illumina shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 0.4% of Illumina shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Illumina and aTyr Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Illumina and aTyr Pharma, as provided by MarketBeat.com.

Illumina presently has a consensus price target of $365.3158, suggesting a potential downside of 16.86%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Illumina.

Volatility and Risk

Illumina has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Illumina and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Illumina has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats aTyr Pharma on 9 of the 14 factors compared between the two stocks.

Agilent Technologies (NYSE:A) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

55.8% of aTyr Pharma shares are owned by institutional investors. 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Agilent Technologies and aTyr Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Agilent Technologies and aTyr Pharma, as provided by MarketBeat.com.

Agilent Technologies presently has a consensus price target of $100.4619, suggesting a potential downside of 17.70%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Agilent Technologies.

Volatility and Risk

Agilent Technologies has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Valuation and Earnings

This table compares Agilent Technologies and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Mettler-Toledo International and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mettler-Toledo International and aTyr Pharma's net margins, return on equity and return on assets.

Institutional and Insider Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 3.2% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Mettler-Toledo International and aTyr Pharma, as provided by MarketBeat.com.

Mettler-Toledo International presently has a consensus price target of $868.0833, suggesting a potential downside of 22.22%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Mettler-Toledo International.

Summary

Mettler-Toledo International beats aTyr Pharma on 8 of the 14 factors compared between the two stocks.

Bio-Rad Laboratories (NYSE:BIO) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Bio-Rad Laboratories and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Rad Laboratories and aTyr Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

63.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 27.5% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Bio-Rad Laboratories has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Bio-Rad Laboratories and aTyr Pharma, as provided by MarketBeat.

Bio-Rad Laboratories presently has a consensus price target of $646.00, suggesting a potential upside of 10.52%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Bio-Rad Laboratories.

Summary

Bio-Rad Laboratories beats aTyr Pharma on 10 of the 13 factors compared between the two stocks.

Waters (NYSE:WAT) and aTyr Pharma (NASDAQ:LIFE) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Waters and aTyr Pharma's gross revenue, earnings per share (EPS) and valuation.

Waters has higher revenue and earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Waters and aTyr Pharma's net margins, return on equity and return on assets.

Institutional & Insider Ownership

91.8% of Waters shares are owned by institutional investors. Comparatively, 55.8% of aTyr Pharma shares are owned by institutional investors. 1.5% of Waters shares are owned by company insiders. Comparatively, 9.4% of aTyr Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Waters has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Waters and aTyr Pharma, as provided by MarketBeat.

Waters presently has a consensus price target of $219.4545, suggesting a potential downside of 19.87%. aTyr Pharma has a consensus price target of $12.00, suggesting a potential upside of 175.86%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Waters.